

Sunil R Hingorani

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4248651/sunil-r-hingorani-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75
papers

13,425
citations

35
h-index

80
g-index

80
ext. papers

16,087
ext. citations

11
avg. IF

5.94
L-index

#	Paper	IF	Citations
75	Cx43 phosphorylation sites regulate pancreatic cancer metastasis. <i>Oncogene</i> , 2021 , 40, 1909-1920	9.2	0
74	Mesenchymal Lineage Heterogeneity Underlies Non-Redundant Functions of Pancreatic Cancer-Associated Fibroblasts. <i>Cancer Discovery</i> , 2021 ,	24.4	12
73	A framework for advancing our understanding of cancer-associated fibroblasts. <i>Nature Reviews Cancer</i> , 2020 , 20, 174-186	31.3	790
72	Magnetic resonance imaging biomarkers for pulsed focused ultrasound treatment of pancreatic ductal adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2020 , 26, 904-917	5.6	4
71	Cholesterol Biosynthesis Influences Subtype Specificity and Plasticity in Pancreas Cancer. <i>Cancer Cell</i> , 2020 , 38, 443-445	24.3	3
70	Increased tumour burden alters skeletal muscle properties in the KPC mouse model of pancreatic cancer. <i>JCSM Rapid Communications</i> , 2020 , 3, 44-55	2.6	1
69	Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3185-3194	2.2	92
68	Non-Invasive Monitoring of Stromal Biophysics with Targeted Depletion of Hyaluronan in Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2019 , 11,	6.6	8
67	Evaluation of Renal Stone Comminution and Injury by Burst Wave Lithotripsy in a Pig Model. <i>Journal of Endourology</i> , 2019 , 33, 787-792	2.7	15
66	Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma. <i>Cancer Immunology Research</i> , 2019 , 7, 977-989	12.5	23
65	A BODIPY-Based Donor/Donor-Acceptor System: Towards Highly Efficient Long-Wavelength-Excitable Near-IR Polymer Dots with Narrow and Strong Absorption Features. <i>Angewandte Chemie</i> , 2019 , 131, 7082-7086	3.6	3
64	Measuring the Economic Burden of Disease and Injury in Korea, 2015. <i>Journal of Korean Medical Science</i> , 2019 , 34, e80	4.7	21
63	Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets. <i>Gastroenterology</i> , 2019 , 156, 2085-2096	13.3	48
62	Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1062-1069	2.2	122
61	Mesenchymal Cell Plasticity and Perfidy in Epithelial Malignancy. <i>Trends in Cancer</i> , 2018 , 4, 273-277	12.5	5
60	Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer. <i>International Journal of Hyperthermia</i> , 2018 , 34, 284-291	3.7	21
59	An in vivo demonstration of efficacy and acute safety of burst wave lithotripsy using a porcine model. <i>Proceedings of Meetings on Acoustics</i> , 2018 , 35,	1	1

58	Evaluation of pancreatic tumor development in KPC mice using multi-parametric MRI. <i>Cancer Imaging</i> , 2018 , 18, 41	5.6	8
57	HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 359-366	2.2	248
56	Noninvasive characterization of pancreatic tumor mouse models using magnetic resonance imaging. <i>Cancer Medicine</i> , 2017 , 6, 1082-1090	4.8	12
55	Photostable Ratiometric Pdot Probe for in Vitro and in Vivo Imaging of Hypochlorous Acid. <i>Journal of the American Chemical Society</i> , 2017 , 139, 6911-6918	16.4	226
54	Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20). <i>Current Oncology Reports</i> , 2017 , 19, 47	6.3	79
53	Runx3 and Cell Fate Decisions in Pancreas Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 962, 333-352	3.6	6
52	T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. <i>Cancer Immunology Research</i> , 2017 , 5, 978-991	12.5	97
51	Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems. <i>Cancer Journal (Sudbury, Mass)</i> , 2017 , 23, 326-332	2.2	3
50	Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 1607-1620	12.9	23
49	Optical painting and fluorescence activated sorting of single adherent cells labelled with photoswitchable Pdots. <i>Nature Communications</i> , 2016 , 7, 11468	17.4	66
48	Tension and Transformation in Pancreas Cancer: Can Phenotype Break Free from the Chrysalis of Genotype?. <i>Cancer Cell</i> , 2016 , 29, 780-782	24.3	1
47	Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 2848-54	12.9	223
46	RUNX3 defines disease behavior in pancreatic ductal adenocarcinoma. <i>Molecular and Cellular Oncology</i> , 2016 , 3, e1076588	1.2	8
45	Gliomas: Motexafin Gadolinium-enhanced Molecular MR Imaging and Optical Imaging for Potential Intraoperative Delineation of Tumor Margins. <i>Radiology</i> , 2016 , 279, 400-9	20.5	7
44	Interim results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 439-439	2.2	15
43	Simultaneous robotic low anterior resection and prostatectomy for adenocarcinoma of rectum and prostate: initial case report. <i>SpringerPlus</i> , 2016 , 5, 1768		7
42	Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , 2016 , 150, 1545-1557.e2	13.3	71
41	Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase. <i>Biophysical Journal</i> , 2016 , 110, 2106-19	2.9	86

40	Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer. <i>Cancer Research</i> , 2015 , 75, 3738-46	10.1	54
39	Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 1764-71	12.9	38
38	T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2015 , 28, 638-652	24.3	129
37	Intercepting Cancer Communiques: Exosomes as Heralds of Malignancy. <i>Cancer Cell</i> , 2015 , 28, 151-3	24.3	8
36	RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. <i>Cell</i> , 2015 , 161, 1345-60	56.2	134
35	Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. <i>Oncologist</i> , 2015 , 20, 143-50	5.7	99
34	High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4006-4006	2.2	23
33	Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 359-359	2.2	12
32	Response to Chauhan et Al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning. <i>Cancer Cell</i> , 2014 , 26, 16-7	24.3	25
31	Stromal reengineering to treat pancreas cancer. <i>Carcinogenesis</i> , 2014 , 35, 1451-60	4.6	84
30	Molecular pathways: myeloid complicity in cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 5157-70	12.9	37
29	Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. <i>Gut</i> , 2014 , 63, 1769-81	19.2	202
28	Re-adapting T cells for cancer therapy: from mouse models to clinical trials. <i>Immunological Reviews</i> , 2014 , 257, 145-64	11.3	60
27	Spatiotemporal proteomic analyses during pancreas cancer progression identifies serine/threonine stress kinase 4 (STK4) as a novel candidate biomarker for early stage disease. <i>Molecular and Cellular Proteomics</i> , 2014 , 13, 3484-96	7.6	18
26	Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E ßocotrienol. <i>Carcinogenesis</i> , 2013 , 34, 858-63	4.6	30
25	Vitamin E ßocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer. <i>Cancer Prevention Research</i> , 2013 , 6, 1074-83	3.2	27
24	Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. <i>Cancer Research</i> , 2013 , 73, 3235-47	10.1	136
23	Changes in connexin43 expression and localization during pancreatic cancer progression. <i>Journal of Membrane Biology</i> , 2012 , 245, 255-62	2.3	20

22	Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. <i>Cancer Cell</i> , 2012 , 21, 418-29	24.3	1309
21	Pancreas cancer meets the thunder god. <i>Science Translational Medicine</i> , 2012 , 4, 156ps21	17.5	7
20	Isoform-specific upregulation of palladin in human and murine pancreas tumors. <i>PLoS ONE</i> , 2010 , 5, e10347	3.7	36
19	A New Preclinical Paradigm for Pancreas Cancer 2010 , 73-93		1
18	Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. <i>Science</i> , 2009 , 324, 1457-61	33.3	2364
17	A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. <i>Clinical Cancer Research</i> , 2008 , 14, 4836-42	12.9	126
16	From Inception to Invasion: Modeling Pathways to Pancreatic Cancer 2008 , 159-179		3
15	Location, location, location: precursors and prognoses for pancreatic cancer. <i>Gastroenterology</i> , 2007 , 133, 345-50	13.3	13
14	Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. <i>Cancer Cell</i> , 2007 , 11, 229-43	24.3	289
13	The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. <i>Cancer Research</i> , 2007 , 67, 6075-82	10.1	95
12	Dynamics of the immune reaction to pancreatic cancer from inception to invasion. <i>Cancer Research</i> , 2007 , 67, 9518-27	10.1	668
11	Targets, trials, and travails in pancreas cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, 1042-53	7.3	10
10	N-cadherin and keratinocyte growth factor receptor mediate the functional interplay between Ki-RASG12V and p53V143A in promoting pancreatic cell migration, invasion, and tissue architecture disruption. <i>Molecular and Cellular Biology</i> , 2006 , 26, 4185-200	4.8	33
9	ATP citrate lyase inhibition can suppress tumor cell growth. <i>Cancer Cell</i> , 2005 , 8, 311-21	24.3	718
8	Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. <i>Cancer Cell</i> , 2005 , 7, 469-83	24.3	1684
7	Ductal pancreatic cancer in humans and mice. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005 , 70, 65-72	3.9	69
6	New pathways to pancreatic cancer. <i>Cancer Biology and Therapy</i> , 2004 , 3, 170-2	4.6	1
5	Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. <i>Cancer Cell</i> , 2004 , 5, 375-87	24.3	612

4	Targeting oncogene dependence and resistance. <i>Cancer Cell</i> , 2003 , 3, 414-7	24.3	21
3	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. <i>Cancer Cell</i> , 2003 , 4, 437-50	24.3	1772
2	Ras redux: rethinking how and where Ras acts. <i>Current Opinion in Genetics and Development</i> , 2003 , 13, 6-13	4.9	73
1	Mesenchymal Lineage Heterogeneity Underlies Non-Redundant Functions of Pancreatic Cancer-Associated Fibroblasts		2